Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Adipose-derived stem cell exosomes suppress NLRP3-mediated neuronal pyroptosis to attenuate seizures in a kainic acid-induced temporal lobe epilepsy model.

Ding S., Chen W., E Y., Zhou J., Zhao S., Chen Y.

Animal Study on Neuroinflammation, published in Front Immunol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Front Immunol (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
41246312
PMCID
PMC12611705
DOI
10.3389/fimmu.2025.1691814
Citations
1

Abstract (original English)

Pyroptosis-mediated neuroinflammation represents a critical pathological mechanism in drug-resistant temporal lobe epilepsy (TLE), while Adipose-derived stem cell exosomes (ADSC-Exos) may target this process through NLRP3 inflammasome inhibition. Our study investigated the therapeutic effects of ADSC-Exos by mitigating NLRP3-driven pyroptosis in TLE. We isolated ADSC-Exos, the characteristics of which were confirmed. The Kainic acid-induced mouse TLE model were used to assess the in vivo effect of ADSC-Exos. To evaluate ADSC-Exos penetration, brain tissues were collected for fluorescence quantification. TUNEL and Nissl staining were used to evaluate hippocampal neuronal damage. Pyroptosis markers were detected by Western blot, qRT-PCR, and immunofluorescence. Bioinformatics analysis was performed to explore potential miRNAs in ADSC-Exos that might contribute to their therapeutic effects. Intravenously injected ADSC-Exos efficiently crossed the blood-brain barrier, peaking in brain accumulation at 4 hours post-administration. Treatment with ADSC-Exos resulted in a 48.9% reduction in seizure duration (p<0.0001) and a 42% reduction in spontaneous recurrent seizure frequency (p<0.0001) in temporal lobe epilepsy. Furthermore, ADSC-Exos exhibited significant neuroprotection while suppressing key pyroptosis-related proteins, including NLRP3, Caspase-1, GSDMD, and IL-1β. Bioinformatics

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsPyroptosisEpilepsy, Temporal LobeNLR Family, Pyrin Domain-Containing 3 ProteinExosomesKainic AcidMiceDisease Models, AnimalMaleNeurons

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research